Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients with Systemic Sclerosis: a 5-year Follow-up Study

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2024 Jan 11

PMID 38206544

Authors

Mihribangvl Alip

Dandan Wang

Shengnan Zhao

Siqi Li

Dongdong Zhang

Xiaoxiao Duan

Shiying Wang

Bingzhu Hua

Hong Wang

Huayong Zhang

Xuebing Feng

Lingyun Sun

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the long-term safety and efficacy of umbilical cord mesenchymal stem cells transplantation (UMSCT) in patients with systemic sclerosis (SSc).

Methods: Forty-one patients with moderate to severe SSc underwent UMSCT at the Affiliated Drum Tower Hospital of Nanjing University Medical School from 2009 to 2017. In this study, we conducted a longitudinal and retrospective analysis and compared the clinical and laboratory manifestations before and after UMSCT. The main outcome of the study was overall survival. We evaluated changes in the modified Rodnan Skin Score (mRSS), as well as the changes in the pulmonary examination by using high-resolution computed tomography (HRCT) and ultrasound cardiogram (UCG). Additionally, we assessed the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the severity of peripheral vascular involvement during the first year after treatment.

Results: The overall 5-year survival rate was 92.7% (38 out of 41 patients). Following UMSCT, the mean mRSS significantly decreased from 18.68 (SD = 7.26, n = 41) at baseline to 13.95 (SD = 8.49, n = 41), 13.29 (SD = 7.67, n = 38), and 12.39 (SD = 8.49, n = 38) at 1, 3, and 5 years, respectively. Improvement or stability in HRCT images was observed in 72.0% of interstitial lung disease (ILD) patients. Pulmonary arterial hypertension (PAH) remained stable in 5 out of 8 patients at the 5-year follow-up. No adverse events related to UMSCT were observed in any of the patients during the follow-up period.

Conclusion: UMSCT may provide a safe and feasible treatment option for patients with moderate to severe SSc based on long-term follow-up data. The randomized controlled study will further confirm the clinical efficacy of UMSCT in SSc.

Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT00962923. Key Point • UMSCT is safe and effective for SSc patients.

Citing Articles

Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study.

Yuan W, Liu M, Yang D, Shi Y, Wang Z, Cao X Stem Cell Res Ther. 2025; 16(1):128.

PMID: 40059221 PMC: 11892273. DOI: 10.1186/s13287-025-04237-1.

Cell-free regenerative medicine: identifying the best source of mesenchymal stem cells for skin therapy in Systemic Sclerosis.

Napolitano F, Giudice V, DEsposito V, Prevete N, Scala P, De Paulis A Front Cell Dev Biol. 2025; 13:1518412.

PMID: 40046231 PMC: 11880212. DOI: 10.3389/fcell.2025.1518412.

Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.

Zeng L, Liu C, Wu Y, Liu S, Zheng Y, Hao W Stem Cell Res Ther. 2025; 16(1):65.

PMID: 39934871 PMC: 11817852. DOI: 10.1186/s13287-025-04184-x.

Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment.

Chen L, Huang R, Huang C, Nong G, Mo Y, Ye L Front Med (Lausanne). 2025; 11:1530887.

PMID: 39882532 PMC: 11774712. DOI: 10.3389/fmed.2024.1530887.

References

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2016; 76(8):1327-1339. DOI: 10.1136/annrheumdis-2016-209909. View

Denton C, Khanna D . Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. View

Hachulla E, Launay D . Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2010; 40(2):78-83. DOI: 10.1007/s12016-010-8198-y. View

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68(5):620-8. DOI: 10.1136/ard.2008.096677. View

Velier M, Daumas A, Simoncini S, Arcani R, Magalon J, Benyamine A . Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis. Bone Marrow Transplant. 2021; 57(1):17-22. DOI: 10.1038/s41409-021-01492-7. View

Snowden J, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z . Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2018; 1(27):2742-2755. PMC: 5745133. DOI: 10.1182/bloodadvances.2017010041. View

Farge D, Loisel S, Lansiaux P, Tarte K . Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmun Rev. 2021; 20(3):102755. DOI: 10.1016/j.autrev.2021.102755. View

Spierings J, van Rhijn-Brouwer F, van Laar J . Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Curr Opin Rheumatol. 2018; 30(6):541-547. DOI: 10.1097/BOR.0000000000000541. View

Burt R, Farge D . Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?. Nat Rev Rheumatol. 2018; 14(4):189-191. DOI: 10.1038/nrrheum.2018.34. View

10.

Farge D, Burt R, Oliveira M, Mousseaux E, Rovira M, Marjanovic Z . Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant. 2017; 52(11):1495-1503. PMC: 5671927. DOI: 10.1038/bmt.2017.56. View

11.

de Castro L, Lopes-Pacheco M, Weiss D, Cruz F, Rocco P . Current understanding of the immunosuppressive properties of mesenchymal stromal cells. J Mol Med (Berl). 2019; 97(5):605-618. DOI: 10.1007/s00109-019-01776-y. View

12.

Le Blanc K, Davies L . Mesenchymal stromal cells and the innate immune response. Immunol Lett. 2015; 168(2):140-6. DOI: 10.1016/j.imlet.2015.05.004. View

13.

Li W, Chen W, Huang S, Tang X, Yao G, Sun L . Mesenchymal Stem Cells Enhance Pulmonary Antimicrobial Immunity and Prevent Following Bacterial Infection. Stem Cells Int. 2020; 2020:3169469. PMC: 7142356. DOI: 10.1155/2020/3169469. View

14.

Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010; 69(8):1423-9. DOI: 10.1136/ard.2009.123463. View

15.

Xu J, Wang D, Liu D, Fan Z, Zhang H, Liu O . Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood. 2012; 120(15):3142-51. PMC: 3471521. DOI: 10.1182/blood-2011-11-391144. View

16.

Liang J, Li X, Zhang H, Wang D, Feng X, Wang H . Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2011; 31(1):157-61. DOI: 10.1007/s10067-011-1816-0. View

17.

Zhang H, Liang J, Tang X, Wang D, Feng X, Wang F . Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther. 2017; 19(1):165. PMC: 5518166. DOI: 10.1186/s13075-017-1373-2. View

18.

Granel B, Daumas A, Jouve E, Harle J, Nguyen P, Chabannon C . Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2014; 74(12):2175-82. PMC: 4680117. DOI: 10.1136/annrheumdis-2014-205681. View

19.

Guillaume-Jugnot P, Daumas A, Magalon J, Jouve E, Nguyen P, Truillet R . Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology (Oxford). 2015; 55(2):301-6. DOI: 10.1093/rheumatology/kev323. View

20.

van Rhijn-Brouwer F, Gremmels H, Fledderus J, Schuurman A, Bonte-Mineur F, Vonk M . A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. BMJ Open. 2018; 8(8):e020479. PMC: 6104757. DOI: 10.1136/bmjopen-2017-020479. View